Home Superbug News - CoronaVirus Watch List

Superbug News - CoronaVirus Watch List

The Superbug Stock Review. Deadly Antibiotic-Resistant Bacteria like ‘Candida Auris’ and Deadly and Virulent Viruses Like ‘CoronaVirus’ or ‘HIV’ which killed 32 million. If Wall Street Funded Biotechs Are Trying to Kill What Wants to Kill Us, We’ll Follow It.

Video: How Superbugs Get Started.

A World Health Organization (WHO) report released April 2014 stated, "this serious threat is no longer a prediction for the future, it is happening...
coronavirus, biotech stock review

VIDEO: Dyadic (DYAI) CEO Explains What his Industry is Doing to Defeat Coronavirus (FoxNews).

Jan. 27, 2020 - 5:24 - Dyadic International CEO Mark Emalfarb discusses what’s being done to stop...
Dyadic

Could Dyadic (DYAI) $5.75 Provide a Solution to Help Mass Produce Vaccines to Battle...

Dyadic (DYAI) has developed a biomanufacturing technology platform, nicknamed C1 which helps to speed the development, lower the manufacturing cost and potentially...

CoronaVirus Watch List Stocks in the News (Bloomberg, Benzinga).

INITIAL WATCHLIST: CoronaVirus Watch List | Superbug Stock Review Aethlon Medical, Inc. (NASDAQ: AEMD) $2.40   Alpha Pro Tech, Ltd. (NYSE: APT)...
Citius Pharmaceutical, CTXR, Biotech Stock Review

New Report: Citius Pharma (CTXR) Now Our #1 Ranked Idea for 2020.

Citius Pharmaceuticals (CTXR) is hands down one of the most exciting long-term opportunities we have come across since we first launched the...
video

Candida Auris: Hospitals mobilize to fight the deadly infection (Video). More Videos Below.

https://youtu.be/hnqFdKSG6-A Auris all over the room, even on the ceiling?.
Dyadic, Biotech Stock Review

Dyadic (DYAI) Highlights.

"In just over a year and a half we have entered into over 15 proof of concept collaborations for both human and...

Adding Citius (CTXR) $0.55 to Watch List.

Best Presentation at Dawson James Conference. We attended the Dawson James Conference on October 29th, which had over 20...
Dyadic, Biotech Stock Review

Dyadic (DYAI) $7.00 Called a ‘Gamechanger’ – Gets $14 Price Target.

Highly Respected Wall Street Analyst Jason Kolbert Issues $14.00 Price Target On Dyadic.

Latest article

Experts From Harvard, Scripps Research Institute, the University Hospital Zürich, and the Former Chief...

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody...

Major Mpox Outbreak in the Democratic Republic of Congo.

As Reported in NPR's Gates and Soda Major Mpox Outbreak in the Democratic Republic of Congo is a...

Mpox Infections Rise to Almost Double Last Year’s Numbers.

The number of mpox cases in 2024 is already nearly double the number of cases that were detected in all of...